Dyadic Announces Nonexclusive Research License with WuXi Biologics

March 30, 2020 9:00 AM

JUPITER, FL / ACCESSWIRE / March 30, 2020 / Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower production costs and improve the performance of biologic vaccines, drugs, and other biologic products, at flexible commercial scales, today announced that it has entered into a...

Read more

Mota Ventures Successful Immune Line Launch Signs Up Over 5,500 New Customers in 12 Days

March 27, 2020 4:50 PM

VANCOUVER, BC / ACCESSWIRE / March 27, 2020 / Mota Ventures Corp. (CSE:MOTA)(FSE:1WZ:GR)(OTCPINK:PEMTF) (the "Company" or "Mota") is pleased to announce that since the launch of its Immune Support product line on March 14, 2020, the Company has acquired over 5,500 new customers seeking natural solutions to help support their family's immune systems. The popularity of the primary product has yielded an average initial...

Read more

Xenetic Biosciences, Inc. Reports 2019 Year End Results and Provides Corporate Update

March 27, 2020 9:00 AM

-Company continues to advance preclinical development of its XCART™ CAR T therapy platform - - Expands XCART resources by adding expertise in cell therapy translational science and CMC - - Cash on hand expected to fund operations through mid-2021 - FRAMINGHAM, MA / ACCESSWIRE / March 27, 2020 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing...

Read more

Apollo Endosurgery, Inc. Reports Fourth Quarter and Full Year 2019 Results

March 26, 2020 4:00 PM

AUSTIN, TX / ACCESSWIRE / March 26, 2020 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, today announced financial results for the fourth quarter and year ended December 31, 2019. The Company will hold a conference call today at 3:30 p.m. CT / 4:30 p.m. ET to discuss its results. Highlights Fourth quarter U.S. OverStitch™...

Read more

Mota Ventures Moves Forward with Its Acquisition of Spanish CBD Company Sativida

March 26, 2020 4:00 AM

VANCOUVER, BC / ACCESSWIRE / March 26, 2020 / Mota Ventures Corp. (CSE:MOTA)(FSE:1WZ:GR)(OTCPINK:PEMTF) (the "Company" or "Mota") is pleased to announce that further to its January 10, 2020 news release, it has now acquired the intellectual property and trade names of Sativida from Sativida OU (Estonia). The Company will license both back to Sativida OU's subsidiary, VIDA BCN LABS S.L. (collectively with Sativida OU,...

Read more

DECN to Add 2nd Covid-19 Test Kit Using Antibody/Antigen Methodology as a Determination Test for Patients Who Previously Tested Positive for Covid-19

March 25, 2020 10:15 AM

COMPANY TO AGAIN SEEK FDA EUA FOR ITS CONFIRMATION KIT MAKING DECN THE FIRST TO OFFER TWO TYPES OF COVID-19 TEST KITS, A SCREENING KIT AND A POST SCREEN CONFIRMATION KIT LOS ANGELES, CA / ACCESSWIRE / March 25, 2020 / Decision Diagnostics Corp. (OTC PINK:DECN) is an 18-year old, diabetes-focused bio-technology development firm, manufacturer, quality plan administrator, FDA registered medical device customer support organization, and...

Read more

Molecular Partners Publishes Invitation to Annual General Meeting 2020

March 25, 2020 2:00 AM

ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / March 25, 2020 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company that is developing a new class of drugs known as DARPin® therapies, today published the invitation to the Annual General Meeting 2020. The Annual General Meeting will be held on Wednesday, April 29, 2020, 2.00 pm CET, at the registered office of the company: Molecular Partners AG, Wagistrasse 14, 5th floor,...

Read more

Apollo Endosurgery, Inc. to Report Fourth Quarter and Full Year 2019 Results on March 26, 2020

March 24, 2020 4:30 PM

AUSTIN, TX / ACCESSWIRE / March 24, 2020 / Apollo Endosurgery, Inc. ("Apollo") (Nasdaq: APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, today announced that the Company is scheduled to release its financial results for the fourth quarter and full year ended December 31, 2019 on Thursday, March 26, 2020, after the U.S. stock markets close. Apollo will hold a conference call on...

Read more

Pieris Pharmaceuticals Provides Update on Servier Collaboration

March 23, 2020 4:30 PM

BOSTON, MA / ACCESSWIRE / March 23, 2020 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory, cancer, and other diseases, today announced an update on its strategic immuno-oncology collaboration with Servier, originally established in 2017. After conducting an extensive portfolio review, Servier has decided...

Read more

Artelo Biosciences to Present at the Spring Investor Summit on March 25th

March 23, 2020 9:00 AM

LA JOLLA, CA / ACCESSWIRE / March 23, 2020 / Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate the endocannabinoid system, announced today that it will be presenting at the 2020 Spring Investor Summit being held on March 25th-26th, featuring over 500 registered executives and investors. Due to the ongoing concerns related to COVID-19, the Spring Investor Summit, which was...

Read more

DECN to Finance 2Q 2020 Roll Out of its GenViro! Covid-19 "Rapid" Kits Using Non-Dilutive Debt Financing Totaling $13 Million Acquired in Near 0% Rate Environment

March 20, 2020 8:55 AM

COMPANY SEIZES OPPORTUNITY TO GET ITS 60 SECOND GENVIRO! "RAPID" KITS INTO THE MARKET, RECEIVES INITIAL DEBT COMMITMENT FROM PRIVATE FUNDS, PRODUCT UPDATES RESUME NEXT WEEK LOS ANGELES, CA / ACCESSWIRE / March 20, 2020 / Decision Diagnostics Corp. (OTC PINK:DECN) is an 18-year old, diabetes-focused bio-technology development firm, manufacturer, quality plan administrator, FDA registered medical device customer support organization,...

Read more

Molecular Partners Publishes Audited Financial Results for 2019 and Annual Report 2019

March 20, 2020 2:00 AM

ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / March 20, 2020 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company that is developing a new class of drugs known as DARPin® therapies, today published its audited Financial Results for 2019 and the company's 2019 Annual Report. The Audited Financial Results for 2019 and the company's 2019 Annual Report are available on the investors section of the company's...

Read more

Nascent Biotech has Begun In Vitro Studies as a Potential Therapeutic Agent Against COVID-19

March 19, 2020 9:45 AM

SAN DIEGO, CA / ACCESSWIRE / March 19, 2020 / Nascent Biotech, Inc. (OTCQB:NBIO), today announced it has begun research on a possible treatment for patients infected with COVID-19. As previously mentioned in the scientific literature (Yu et al. Journal of Biomedical Science (2016) 23:14 DOI 10.1186/s12929-016-0234-7) Pritumumab's specific target, cell surface vimentin, is a potential target in the treatment of conditions related to...

Read more

Dyadic Presents New Business Opportunities to Address COVID-19, Influenza and Continued Scientific and Business Development Progress

March 18, 2020 4:15 PM

JUPITER, FL / ACCESSWIRE / March 18, 2020 / Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower production costs and improve the performance of biologic vaccines, drugs, and other biologic products, at flexible commercial scales, today announced that its management...

Read more

Aqualung Therapeutics Advances Its Investigational Monoclonal Antibody into IND-Enabling Studies of Acute Respiratory Distress Syndrome (ARDS) And Ventilator-Induced Lung Injury (VILI)

March 18, 2020 3:05 PM

COVID-19 and exposure to mechanical ventilation increase unchecked inflammation and ARDS mortality(ARDS) AND VENTILATOR-INDUCED LUNG INJURY (VILI) TUCSON, AZ / ACCESSWIRE / March 18, 2020 / Aqualung Therapeutics Corporation is developing ALT-100, a therapeutic monoclonal antibody, to combat serious unchecked inflammation. The initial application aims to reduce the mortality of Acute Respiratory Distress Syndrome (ARDS) and Ventilator-Induced...

Read more

Stem Cell Therapy for the Coronavirus COVID-19 Pandemic

March 18, 2020 12:00 PM

GOLDEN, CO / ACCESSWIRE / March 18, 2020 / Vitro Diagnostics, Inc. (OTC PINK:VODG), dba Vitro Biopharma reports on its therapy for the Coronavirus (COVID-19) pandemic. Recent umbilical cord stem cell therapies in China to fight the Coronavirus are producing encouraging safety and efficacy...

Read more

Calmare Therapeutics CEO Issues Statement

March 16, 2020 2:58 PM

FAIRFIELD, CT / ACCESSWIRE / March 16, 2020 / Responding to the COVID-19 pandemic ("CoronaVirus"), Conrad Mir, President & CEO of Calmare Therapeutics Incorporated, (OTC PINK:CTTC), the pain mitigation company, issued the following statement: To the shareholders, customers, family and friends of Calmare Therapeutics. We hope this email finds you and your family doing well during this troubling and difficult time. Calmare...

Read more

Dyadic to Report Year End 2019 Financial Results on Monday, March 30, 2020

March 16, 2020 8:00 AM

JUPITER, FL / ACCESSWIRE / March 16, 2020 / Dyadic International, Inc. ("Dyadic") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 expression system to speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced that it will report its financial results for year ended December 31, 2019 after the...

Read more

Edesa Biotech to Develop Novel Treatment for Vitiligo in Collaboration with the National Research Council of Canada

March 12, 2020 7:30 AM

TORONTO, ON / ACCESSWIRE / March 12, 2020 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, today announced a collaborative research project with the National Research Council of Canada (NRC) to develop novel immunotherapies for vitiligo as well as other indications. Vitiligo is a life-altering autoimmune disease that results in the depigmenting of the skin. People who have vitiligo develop white patches of skin...

Read more

Pieris Pharmaceuticals Reports Full-Year 2019 Financial Results And Provides Corporate Update

March 12, 2020 7:00 AM

COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON THURSDAY, MARCH 12, 2020 AT 8:00 AM EDT BOSTON, MA / ACCESSWIRE / March 12, 2020 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory, cancer, and other diseases, today reported financial results for its fiscal year ended December 31, 2019 and provided an...

Read more